Clinical observation on rapid relief of dyspnea in juvenile-onset recurrent respiratory papillomatosis treated with bevacizumab
10.3760/cma.j.cn115330-20240701-00393
- VernacularTitle:贝伐珠单抗对幼年型复发性呼吸道乳头状瘤病呼吸困难缓解作用的临床观察
- Author:
Yufei PAN
1
;
Zhenkun YU
;
Yuanyuan LU
;
Huili HUANG
;
Kai LIU
;
Huiying HU
;
Yonghui ZHANG
Author Information
1. 南京医科大学附属明基医院耳鼻咽喉头颈外科，南京 210019
- Publication Type:Journal Article
- Keywords:
Dyspnea;
Juvenile-onset recurrent respiratory papillomatosis;
Bevacizumab
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2025;60(1):52-57
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of bevacizumab in reducing dyspnea, avoiding tracheostomy, and assessing the overall safety and effectiveness of the treatment in patients with juvenile-onset recurrent respiratory papillomatosis (JORRP).Methods:This study included 19 patients with JORRP treated with Bevacizumab at the Department of Otolaryngology-Head and Neck Surgery, BenQ Medical Center, from March 2022 to June 2024. The age of patients ranged from 1.0 to 27.0 years (10.47±8.45 years), with age at onset ranging from 0.5 to 15.0 years (3.66±3.70 years). The cohort included 11 males and 8 females. Bevacizumab was administered intravenously at a dose of 10 mg/kg every three weeks for three sessions. Efficacy was evaluated by comparing the standardized lesion volume pre-and post-treatment, with statistical analysis performed using R software (4.3.1).Results:Among the 19 patients, 11 presented with dyspnea before treatment. All patients experienced varying degrees of dyspnea relief within 72 hours following the initial treatment, and only one patient had mild dyspnea by the second treatment session three weeks later. The average reduction rates at 24 and 48 hours post-initia treatment were 25.75% and 47.16%, respectively. Following three treatment cycles, the average cumulative reduction rate was 67.47%, significantly higher than after the first treatment ( Z=3.38, P=0.002). Throughout the treatment period, no adverse events that of grade 2 or higher were noted. Conclusions:Bevacizumab can rapidly alleviate dyspnea symptoms and significantly reduce lesion volume in JORRP patients, exhibiting satisfactory overall safety and effectiveness. However additional large-scale prospective studies are warranted to validate its long-term safety and efficacy.
